# Decoding Microbiota in Genitourinary Oncology: Biological Mechanisms and Clinical Implications—A Narrative Review

## TL;DR

This review explores how gut and other microbiota influence genitourinary cancers and treatment responses, highlighting potential for precision medicine.

## Contribution

The paper synthesizes current evidence on microbiota's role in genitourinary cancers, emphasizing biological mechanisms and clinical correlations.

## Key findings

- Altered microbiota profiles correlate with oncogenic signaling and tumor microenvironment changes.
- Microbial ecosystems modulate immune and metabolic processes, affecting responses to immunotherapy.
- Early studies suggest microbiota modulation could improve therapeutic outcomes in some cancer types.

## Abstract

Genitourinary cancers are common malignancies that often display substantial variability in their clinical course and response to treatment. In recent years, increasing attention has focused on human microbiota as a biological factor capable of influencing inflammatory, immune and metabolic processes. Growing evidence suggests that alterations in microbial communities may contribute to cancer development and modulate therapeutic outcomes. This review provides an overview of current research on the involvement of microbiota in renal, prostate, bladder and testicular cancers. It summarizes key biological mechanisms and clinically relevant observations that have contributed to the rising interest in this field.

Genitourinary malignancies are characterized by marked heterogeneity in tumor biology, clinical behavior and therapeutic outcomes. Despite significant progress in surgical and systemic treatments, resistance to therapy remains a major challenge, highlighting the need to identify additional host-related determinants of disease progression and treatment response. Within this framework, converging experimental and clinical evidence indicates that host-associated microbial ecosystems may influence key biological processes involved in tumor–host interactions, including immune modulation, metabolic regulation and inflammatory pathways. Altered microbial profiles have been associated with oncogenic signaling, changes in the tumor microenvironment and differences in clinical benefit from systemic therapies, particularly immunotherapeutic approaches. This review brings together preclinical, translational and clinical evidence on the involvement of microbiota in renal, prostate, bladder and testicular cancers, with attention to biological mechanisms and clinically meaningful correlations with disease characteristics. While current data are largely observational, early interventional studies suggest that modulation of microbial ecosystems may influence therapeutic activity in selected clinical settings. Collectively, these findings support microbiota as a relevant component of genitourinary cancer biology with potential implications for precision medicine approaches.